American Airlines (AAL) Stock Falls After Q4 Capacity Forecast Reduced Amid Trav...
American Airlines (AAL) cuts Q4 capacity forecast to 6.5% amid falling TSA numbers, while institutional buyers add $119M stake. St...
Dick’s Sporting Goods (DKS) Q2 Earnings Preview: Foot Locker Integration Takes C...
Dick's Sporting Goods (DKS) reports Q2 earnings Tuesday. Analysts expect $3.78 EPS and $5.65B revenue as Foot Locker acquisition p...
Visa (V) Stock Surges to 52-Week Peak Amid Strong Analyst Backing
Visa (V) stock climbed to a 52-week high of $374.20, driven by strong Q3 earnings, double-digit revenue growth, and bullish analys...
XPeng (XPEV) Stock: Falls 6.8% Despite $900 Million Robotics Funding Boost
TLDR XPeng shares slide 6.8% even as its robotics unit secures over $900 million. XPeng robotics reaches a valuation above $6.3 bi...
Pfizer (PFE) Stock: Analysts Lean Bullish Despite Lingering Valuation Questions
Pfizer (PFE) stock trades at 9.4x 2026 earnings with a 6.1% dividend yield. Wall Street says Moderate Buy, but valuation questions...
CrowdStrike (CRWD) Stock: Wall Street Anticipates 8% Volatility on Q2 Earnings R...
CrowdStrike (CRWD) reports Q2 earnings Wednesday. Analysts expect $1.44B revenue, 8% stock movement, and raised price targets amid...
Goverment Shutdown 2026 Odds Fall as Markets Split the October 1 Risk
Government shutdown odds fell on Kalshi while Polymarket showed a split picture, offering crypto traders a dated read on fiscal ri...
Expion Energy (XPON) Stock Soars 118% on Louisiana Oil Deal and Leadership Shake...
Expion Energy (XPON) stock surged 118% after a $9M raise, $3.4M Louisiana oil acquisition, rebranding to Expion Energy, and appoin...
Zondacrypto boss seeks leniency for testimony on political ties: Report
Przemysław Kral reportedly faces a fraud charge and is cooperating with Polish prosecutors as estimated customer losses reach $650...
SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress
SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid rising...